Send us Feedback

Isis Pharmaceuticals (ISIS)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

ISIS » Topics » Item 9.01. Financial Statements and Exhibits.

This excerpt taken from the ISIS 8-K filed Nov 17, 2009.
Financial Statements and Exhibits.

 

(d)  Exhibits.

 

99.1                                     Press Release dated November 17, 2009. 

 

2


 

This excerpt taken from the ISIS 8-K filed Nov 5, 2009.

Item 9.01.      Financial Statements and Exhibits.

 

(d)  Exhibits.

 

99.1

Press Release dated November 5, 2009.

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

ISIS PHARMACEUTICALS, INC.

 

 

 

 

Dated: November 4, 2009

By:

/s/ B. Lynne Parshall

 

 

B. LYNNE PARSHALL

 

 

Chief Operating Officer,

 

 

Chief Financial Officer and Director

 

3


 

INDEX TO EXHIBITS

 

99.1

Press Release dated November 5, 2009.

 

4

This excerpt taken from the ISIS 8-K filed Oct 21, 2009.

Item 9.01.              Financial Statements and Exhibits.

 

(d)  Exhibits.

 

99.1

Press Release dated October 21, 2009.

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

ISIS PHARMACEUTICALS, INC.

 

 

 

 

Dated: October 21, 2009

By:

/s/ B. Lynne Parshall

 

 

B. LYNNE PARSHALL

 

 

Chief Operating Officer,

 

 

Chief Financial Officer and Director

 

3


 

INDEX TO EXHIBITS

 

99.1         Press Release dated October 21, 2009. 

 

4

This excerpt taken from the ISIS 8-K filed Aug 6, 2009.

Item 9.01.  Financial Statements and Exhibits.

 

(d)  Exhibits.

 

99.1

 

Press Release dated August 6, 2009.

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

ISIS PHARMACEUTICALS, INC.

 

 

 

 

 

 

Dated: August 5, 2009

By:

/s/ B. LYNNE PARSHALL

 

 

B. LYNNE PARSHALL

 

 

Chief Operating Officer,

 

 

Chief Financial Officer and Director

 

3


 

INDEX TO EXHIBITS

 

99.1                                                                           Press Release dated August 6, 2009.

 

4

This excerpt taken from the ISIS 8-K filed Jun 4, 2009.

Item 9.01.              Financial Statements and Exhibits.

 

(d)  Exhibits.

 

3.1              Amended and Restated Bylaws of Isis Pharmaceuticals, Inc.

 

3


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

ISIS PHARMACEUTICALS, INC.

 

 

 

 

 

 

Dated: June 2, 2009

By:

/s/ B. Lynne Parshall

 

 

B. LYNNE PARSHALL

 

 

Chief Financial Officer and Chief Operating Officer

 

4


 

INDEX TO EXHIBITS

 

3.1           Amended and Restated Bylaws of Isis Pharmaceuticals, Inc.

 

5

This excerpt taken from the ISIS 8-K filed May 20, 2009.

Item 9.01.              Financial Statements and Exhibits.

 

(d)  Exhibits.

 

99.1

 

Press Release dated May 20, 2009.

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

ISIS PHARMACEUTICALS, INC.

 

 

 

 

 

Dated: May 20, 2009

By:

/s/ B. Lynne Parshall

 

 

B. LYNNE PARSHALL

 

 

Chief Operating Officer,

 

 

Chief Financial Officer and Director

 

3


 

INDEX TO EXHIBITS

 

99.1

 

Press Release dated May 20, 2009.

 

4

This excerpt taken from the ISIS 8-K filed May 7, 2009.

Item 9.01.  Financial Statements and Exhibits.

 

(d)  Exhibits.

 

99.1

 

Press Release dated May 7, 2009.

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

ISIS PHARMACEUTICALS, INC.

 

 

 

 

Dated: May 7, 2009

By:

/s/ B. Lynne Parshall

 

 

B. LYNNE PARSHALL

 

 

Chief Operating Officer,

 

 

Chief Financial Officer and Director

 

INDEX TO EXHIBITS

 

99.1

 

Press Release dated May 7, 2009.

 

3

This excerpt taken from the ISIS 8-K filed Apr 29, 2009.

Item 9.01.              Financial Statements and Exhibits.

 

(d)  Exhibits.

 

99.1

 

Press Release dated April 29, 2009. 

 

 SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

ISIS PHARMACEUTICALS, INC.

 

 

 

 

 

 

Dated: April 28, 2009

By:

/s/ B. Lynne Parshall

 

 

B. LYNNE PARSHALL

 

 

Chief Operating Officer,

 

 

Chief Financial Officer and Director

 

2

This excerpt taken from the ISIS 8-K filed Apr 15, 2009.

Item 9.01.              Financial Statements and Exhibits.

 

(d)

Exhibits.

 

 

 

 

 

99.1

1989 Stock Option Plan, as amended.

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

ISIS PHARMACEUTICALS, INC.

 

 

 

 

 

 

Dated: April 10, 2009

By:  

/s/ B. Lynne Parshall

 

 

B. LYNNE PARSHALL

 

 

Executive Vice President,

 

 

Chief Financial Officer and Director

 

3


 

INDEX TO EXHIBITS

 

99.1

 

1989 Stock Option Plan, as amended.

 

4

This excerpt taken from the ISIS 8-K filed Mar 4, 2009.

Item 9.01.              Financial Statements and Exhibits.

 

(d)  Exhibits.

 

99.1

Press Release dated March 4, 2009.

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

ISIS PHARMACEUTICALS, INC.

 

 

 

 

Dated: March 3, 2009

By:

/s/ B. Lynne Parshall

 

 

B. LYNNE PARSHALL

 

 

Chief Operating Officer,

 

 

Chief Financial Officer and Director

 

3


 

INDEX TO EXHIBITS

 

99.1

Press Release dated March 4, 2009.

 

4

This excerpt taken from the ISIS 8-K filed Feb 25, 2009.

Item 9.01.      Financial Statements and Exhibits.

 

(d)  Exhibits.

 

99.1                           Press Release dated February 25, 2009.

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

ISIS PHARMACEUTICALS, INC.

 

 

 

 

Dated: February 24, 2009

By:

/s/ B. Lynne Parshall

 

 

B. LYNNE PARSHALL

 

 

Chief Operating Officer,

 

 

Chief Financial Officer and Director

 

3


 

INDEX TO EXHIBITS

 

99.1                           Press Release dated February 25, 2009.

 

4

EXCERPTS ON THIS PAGE:

8-K
Nov 17, 2009
8-K
Nov 5, 2009
8-K
Oct 21, 2009
8-K
Aug 6, 2009
8-K
Jun 4, 2009
8-K
May 20, 2009
8-K
May 7, 2009
8-K
Apr 29, 2009
8-K
Apr 15, 2009
8-K
Mar 4, 2009
8-K
Feb 25, 2009

RELATED TOPICS for ISIS:

"Item 9.01. Financial Statements and Exhibits." elsewhere:

Bristol-Myers Squibb Company (BMY)
Adolor (ADLR)
Allos Therapeutics (ALTH)
Alexion Pharmaceuticals (ALXN)
Arena Pharmaceuticals (ARNA)
ArQule (ARQL)
Sarepta Therapeutics, Inc. (AVII)
AVANIR Pharmaceuticals (AVNR)
Cubist Pharmaceuticals (CBST)
Cephalon (CEPH)
CoreSite Realty Corp (COR)
DepoMed (DEPO)
Durect (DRRX)
DUSA Pharmaceuticals (DUSA)
ENDO HEALTH SOLUTIONS INC. (ENDP)
Forest Laboratories (FRX)
Geron (GERN)
Inspire Pharmaceuticals (ISPH)
Kendle International (KNDL)
Lannett Co (LCI)
Ligand Pharmaceuticals (LGND)
Medicines Company (MDCO)
NeurogesX (NGSX)
Neurogen (NRGN)
NitroMed (NTMD)
Orexigen Therapeutics (OREX)
PDL BioPharma (PDLI)
Pozen (POZN)
Pain Therapeutics (PTIE)
SciClone Pharmaceuticals (SCLN)
Sunovion Pharmaceuticals Inc. (SEPR)
Shire (SHPGY)
SIGA Technologies (SIGA)
Santarus (SNTS)
Astex Pharmaceuticals, Inc (SUPG)
United Therapeutics (UTHR)
Warner Chilcott (WCRX)
Allergan (AGN)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki